Literature DB >> 9765243

Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin.

Z Valnickova1, J J Enghild.   

Abstract

Procarboxypeptidase U (EC 3.4.17.20) (pro-CpU), also known as plasma procarboxypeptidase B and thrombin-activable fibrinolysis inhibitor, is a human plasma protein that has been implicated in the regulation of fibrinolysis. In this study, we show that pro-CpU serves as a substrate for transglutaminases. Both factor XIIIa and tissue transglutaminase catalyzed the polymerization of pro-CpU and the cross-linking to fibrin as well as the incorporation of 5-dimethylaminonaphthalene-1-sulfonyl cadaverine (dansylcadaverine), [14C]putrescine, and dansyl-PGGQQIV. These findings show that pro-CpU contains both amine acceptor (Gln) and amine donor (Lys) residues. The amine acceptor residues were identified as Gln2, Gln5, and Gln292, suggesting that both the activation peptide and the mature enzyme participate in the cross-linking reaction. These observations imply that transglutaminases may mediate covalent binding of pro-CpU to other proteins and cell surfaces in vivo. In particular, factor XIIIa may cross-link pro-CpU to fibrin during the latter part of the coagulation cascade, thereby helping protect the newly formed fibrin clot from premature plasmin degradation. Moreover, the cross-linking may facilitate the activation of pro-CpU, stabilize the enzymatic activity, and protect the active enzyme from further degradation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765243     DOI: 10.1074/jbc.273.42.27220

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

Review 2.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

3.  Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.

Authors:  Prakash G Doiphode; Marina V Malovichko; Kelly Njine Mouapi; Muriel C Maurer
Journal:  Anal Biochem       Date:  2014-04-19       Impact factor: 3.365

4.  Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot.

Authors:  Camilla Lund Nikolajsen; Thomas F Dyrlund; Ebbe Toftgaard Poulsen; Jan J Enghild; Carsten Scavenius
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

5.  Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.

Authors:  Anna D Protopopova; Andrea Ramirez; Dmitry V Klinov; Rustem I Litvinov; John W Weisel
Journal:  J Thromb Haemost       Date:  2019-03-14       Impact factor: 5.824

Review 6.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

7.  Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.

Authors:  Zuzana Valnickova; Laura Sanglas; Joan L Arolas; Steen V Petersen; Christine Schar; Daniel Otzen; Francesc X Aviles; F Xavier Gomis-Rüth; Jan J Enghild
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

Review 8.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

9.  Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice.

Authors:  Sravya Kattula; James R Byrnes; Sara M Martin; Lori A Holle; Brian C Cooley; Matthew J Flick; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-01-03

10.  Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Authors:  Zuzana Valnickova; Morten Thaysen-Andersen; Peter Højrup; Trine Christensen; Kristian W Sanggaard; Torsten Kristensen; Jan J Enghild
Journal:  BMC Biochem       Date:  2009-05-05       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.